Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995.
The newly developed long-acting somatostatin analogue SMS 201-995 was used to treat a patient with the presumptive diagnosis of benign insulinoma. Although intermittent injections with 50-100 micrograms s.c. every 8 h failed to produce any clinical improvement, continuous s.c. infusion with 150-300 micrograms/day prevented the hypoglycemic episodes absolutely, both during normal dietary intake and throughout 72 h of fasting. Chronic treatment (to date 30 months) has not been associated with any evidence of tachyphylaxis or rebound hypersecretion of insulin.
Glaser
B
B
Department of Endocrinology and Metabolism, Hadassah University Hospital, Jerusalem, Israel.
Rösler
A
A
Halperin
Y
Y
D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D003692:Delayed-Action Preparations; D005951:Glucose Tolerance Test; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D007260:Infusion Pumps; D007263:Infusions, Parenteral; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood; D007340:Insulinoma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D013997:Time Factors
D001786:Blood Glucose; D003692:Delayed-Action Preparations; D007328:Insulin; D015282:Octreotide